Reported positions
Quarter-end holdings as filed
Explore the full published position list and its source filing. This record excludes the manager’s cash, shorts and non-13(f) assets.
Soleus Capital Management, L.P.
A quarter-end snapshot. Filed up to 45 days later, so this page is not current holdings and never a complete portfolio. what a 13F is — and is not ↓ · methodology §13F ↗
Period
$2.5B
reported valuesum of disclosed values for 2026-03-31; 0 positions carry a NULL value and are excluded from the sum, surfaced here rather than folded away
93
positionsALL retained default holdings for this (filer, period), including NULL-value ones
25
new stakespositions with no comparable holding in the prior quarter (kind new), 2026-03-31
27
exitspositions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
Position changes — into 2026-03-31
by shares · Δ value · filing link · how changes are classified §Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
KRYSTAL BIOTECH INC COMposition key pos:17789 · issuer key iss:1307 | add | +$65.9M | +212,028 | $232M | $298M | 941,059 | 1,153,087 | |
CELCUITY INC COMposition key pos:11232 · issuer key iss:542 | trim | −$33.8M | −523,880 | $180M | $147M | 1,808,258 | 1,284,378 | |
TG THERAPEUTICS INC COMposition key pos:18173 · issuer key iss:2129 | add | +$40.3M | +890,007 | $93.6M | $134M | 3,139,312 | 4,029,319 | |
INSULET CORP COMposition key pos:18144 · issuer key iss:1190 | add | +$75.4M | +412,500 | $42.6M | $118M | 150,000 | 562,500 | |
NOVOCURE LTD ORD SHSposition key sid:sec:prov:ab3bd82b93cc9c55eaac96fb008434de · issuer key cusip6:G6674U | add | +$4.1M | +1,961,726 | $110M | $114M | 8,530,665 | 10,492,391 | |
UNITED THERAPEUTICS CORP DEL COMposition key pos:15902 · issuer key iss:2217 | add | +$81.8M | +127,187 | $29.2M | $111M | 60,000 | 187,187 | |
PRAXIS PRECISION MEDICINES I COM NEWposition key pos:11991 · issuer key iss:1748 | trim | −$491K | −32,449 | $107M | $106M | 362,966 | 330,517 | |
VERICEL CORP COMposition key pos:15641 · issuer key iss:2261 | add | +$54.5M | +1,785,079 | $27.5M | $82.0M | 764,000 | 2,549,079 | |
ALKERMES PLC SHSposition key pos:16418 · issuer key iss:2418 | add | +$32.7M | +648,500 | $37.0M | $69.7M | 1,322,364 | 1,970,864 | |
ANI PHARMACEUTICALS INC COMposition key pos:13977 · issuer key iss:27 | add | +$24.7M | +334,000 | $38.4M | $63.1M | 486,243 | 820,243 | |
GLOBUS MED INC CL Aposition key pos:17909 · issuer key iss:1017 | trim | −$14.6M | −157,533 | $77.4M | $62.9M | 887,000 | 729,467 | |
GERON CORP COMposition key sid:sec:prov:b6aaf2a1d9a7b3e3e2f1185e3325ec7d · issuer key cusip6:374163 | add | +$31.1M | +18,218,659 | $30.7M | $61.8M | 23,290,000 | 41,508,659 | |
TWIST BIOSCIENCE CORP COMposition key pos:18059 · issuer key iss:2177 | trim | −$767K | −635,173 | $59.1M | $58.3M | 1,861,802 | 1,226,629 | |
EDGEWISE THERAPEUTICS INC COMposition key pos:12663 · issuer key iss:796 | add | +$23.1M | +539,915 | $22.6M | $45.7M | 910,000 | 1,449,915 | |
BETA BIONICS INC COMposition key sid:sec:prov:4e7eb09ab13c64fd6730ede8dbc988b8 · issuer key cusip6:08659B | add | −$33.6M | +1,819,936 | $77.2M | $43.6M | 2,534,565 | 4,354,501 | |
ALNYLAM PHARMACEUTICALS INC COMposition key pos:16018 · issuer key iss:150 | add | +$15.7M | +61,650 | $27.8M | $43.6M | 70,000 | 131,650 | |
SYNDAX PHARMACEUTICALS INC COMposition key sid:sec:prov:eb359106a5c4d721cdc955ced4da0795 · issuer key cusip6:87164F | trim | −$6.9M | −520,202 | $47.2M | $40.3M | 2,247,110 | 1,726,908 | |
INDIVIOR PHARMACEUTICALS INC COMposition key pos:18425 · issuer key iss:1171 | new | +$38.8M | +1,274,000 | $0 | $38.8M | — | 1,274,000 | |
NEUROPACE INC COMposition key sid:sec:prov:3402bbe7c4ba34aeef0c97588550f290 · issuer key cusip6:641288 | add | −$3.2M | +228,999 | $41.7M | $38.6M | 2,703,208 | 2,932,207 | |
LIVANOVA PLC SHSposition key pos:11842 · issuer key iss:2558 | add | +$2.1M | +15,000 | $34.9M | $37.0M | 567,500 | 582,500 | |
MIRUM PHARMACEUTICALS INC COMposition key pos:12357 · issuer key iss:1485 | trim | −$8.3M | −173,308 | $45.3M | $37.0M | 573,614 | 400,306 | |
BIOMARIN PHARMACEUTICAL INC COMposition key pos:11882 · issuer key iss:375 | trim | −$41.7M | −669,428 | $78.4M | $36.8M | 1,320,000 | 650,572 | |
PROGYNY INC COMposition key pos:18076 · issuer key iss:1766 | new | +$35.1M | +2,067,000 | $0 | $35.1M | — | 2,067,000 | |
INSPIRE MED SYS INC COMposition key pos:14444 · issuer key iss:1183 | add | +$2.1M | +276,900 | $27.6M | $29.7M | 299,399 | 576,299 | |
KINIKSA PHARMACEUTICALS INTL ORD SHS CL Aposition key pos:14218 · issuer key iss:2550 | trim | +$889K | −65,647 | $24.2M | $25.1M | 587,000 | 521,353 | |
MERCK & CO INC COMposition key pos:18668 · issuer key iss:1461 | new | +$24.4M | +203,000 | $0 | $24.4M | — | 203,000 | |
ORGANOGENESIS HLDGS INC COMposition key sid:sec:prov:dbdd1ea895d57b4689152f8bb7b4c066 · issuer key cusip6:68621F | add | −$27.8M | +100,000 | $51.7M | $23.9M | 9,985,951 | 10,085,951 | |
NATERA INC COMposition key pos:14059 · issuer key iss:1529 | add | +$19.2M | +99,000 | $4.6M | $23.8M | 20,000 | 119,000 | |
AXOGEN INC COMposition key sid:sec:prov:fd61a14f8c16900d70648b14bc187bfb · issuer key cusip6:05463X | trim | −$17.0M | −527,685 | $39.5M | $22.5M | 1,206,855 | 679,170 | |
VAXCYTE INC COMposition key pos:12513 · issuer key iss:2248 | trim | −$5.7M | −223,486 | $28.1M | $22.4M | 608,958 | 385,472 | |
ICON PLC SHSposition key pos:16474 · issuer key iss:2532 | new | +$21.2M | +192,000 | $0 | $21.2M | — | 192,000 | |
CERUS CORP COMposition key sid:sec:prov:5acb3fdf8cac3eec6cd20dcb98ac92d0 · issuer key cusip6:157085 | add | +$11.3M | +6,753,700 | $8.2M | $19.6M | 4,000,000 | 10,753,700 | |
TREVI THERAPEUTICS INC COMposition key pos:18739 · issuer key iss:2160 | add | +$8.1M | +720,000 | $11.3M | $19.3M | 900,000 | 1,620,000 | |
CONTEXT THERAPEUTICS INC COMposition key sid:sec:prov:1e37f227d26a900c417273e355bd6875 · issuer key cusip6:21077P | new | +$18.2M | +6,963,141 | $0 | $18.2M | — | 6,963,141 | |
VIR BIOTECHNOLOGY INC COMposition key pos:14363 · issuer key iss:2275 | new | +$17.9M | +2,002,000 | $0 | $17.9M | — | 2,002,000 | |
XENON PHARMACEUTICALS INC COMposition key pos:13384 · issuer key iss:2365 | new | +$17.0M | +292,000 | $0 | $17.0M | — | 292,000 | |
TRAVERE THERAPEUTICS INC COMposition key pos:18617 · issuer key iss:2158 | new | +$16.2M | +546,000 | $0 | $16.2M | — | 546,000 | |
TANDEM DIABETES CARE INC COM NEWposition key sid:sec:prov:19588aa5d3ea91e99dd9f4e2dc8228b5 · issuer key cusip6:875372 | new | +$15.0M | +783,000 | $0 | $15.0M | — | 783,000 | |
NURIX THERAPEUTICS INC COMposition key sid:sec:prov:48ac0f50c981e01f7c5af17d58a117cf · issuer key cusip6:67080M | trim | −$8.6M | −281,231 | $23.1M | $14.5M | 1,219,394 | 938,163 | |
UROGEN PHARMA LTD COMposition key sid:sec:prov:a469da6cabfc03832e3d85a7bff09e97 · issuer key cusip6:M96088 | add | +$9.6M | +577,000 | $3.5M | $13.1M | 150,000 | 727,000 | |
SIONNA THERAPEUTICS INC COMposition key pos:11054 · issuer key iss:1980 | add | +$720K | +25,000 | $11.0M | $11.8M | 268,500 | 293,500 | |
CORCEPT THERAPEUTICS INC COMposition key pos:16992 · issuer key iss:652 | new | +$11.5M | +285,531 | $0 | $11.5M | — | 285,531 | |
VERACYTE INC COMposition key pos:15789 · issuer key iss:2254 | add | +$9.9M | +309,912 | $421K | $10.3M | 10,000 | 319,912 | |
ORTHOPEDIATRICS CORP COMposition key sid:sec:prov:71e6d7a9978be392e4db6948ea1b496a · issuer key cusip6:68752L | add | +$435K | +90,000 | $9.3M | $9.8M | 525,447 | 615,447 | |
ARCUS BIOSCIENCES INC COMposition key sid:sec:prov:3c51cfeec4a5be695bdb08ebfaa41e00 · issuer key cusip6:03969F | trim | −$7.2M | −260,000 | $17.0M | $9.8M | 711,983 | 451,983 | |
TANGO THERAPEUTICS INC COMposition key pos:12388 · issuer key iss:2086 | add | +$9.3M | +440,000 | $88.6K | $9.4M | 10,000 | 450,000 | |
EVOLUS INC COMposition key sid:sec:prov:3c1bdde45f78766466db92da273259f5 · issuer key cusip6:30052C | add | +$2.1M | +1,175,360 | $7.1M | $9.2M | 1,070,000 | 2,245,360 | |
SOPHIA GENETICS SA ORDINARY SHARESposition key sid:sec:prov:59cedce491af5848a83a9f890d8ec6fe · issuer key cusip6:H82027 | new | +$9.2M | +1,850,000 | $0 | $9.2M | — | 1,850,000 | |
ENLIVEN THERAPEUTICS INC COMposition key sid:sec:prov:bf437640b37b30ed62d091e5e9de5808 · issuer key cusip6:29337E | trim | −$6.7M | −794,131 | $15.8M | $9.1M | 1,025,000 | 230,869 | |
INHIBRX BIOSCIENCES INC COMposition key pos:16847 · issuer key iss:1178 | add | +$6.8M | +106,000 | $2.0M | $8.8M | 25,000 | 131,000 | |
DEXCOM INC COMposition key pos:15920 · issuer key iss:727 | trim | −$77.3M | −1,157,094 | $86.1M | $8.8M | 1,297,094 | 140,000 | |
SEPTERNA INC COMposition key sid:sec:prov:c07b19289bd1953ef889bf232426771d · issuer key cusip6:81734D | trim | −$4.1M | −108,368 | $10.7M | $6.6M | 383,368 | 275,000 | |
BIODESIX INC COMposition key sid:sec:prov:2452fdde4d0b3fb9db6ac52c91059345 · issuer key cusip6:09075X | new | +$6.0M | +416,599 | $0 | $6.0M | — | 416,599 | |
RELMADA THERAPEUTICS INC COMposition key sid:sec:prov:0492e747c8d37a4dab1ade9330576c2c · issuer key cusip6:75955J | new | +$5.9M | +842,106 | $0 | $5.9M | — | 842,106 | |
CULLINAN THERAPEUTICS INC COMposition key pos:13492 · issuer key iss:693 | new | +$5.8M | +410,200 | $0 | $5.8M | — | 410,200 | |
IMMUNOVANT INC COMposition key sid:sec:prov:c0680e314bfe2d1131f5c3d642c67920 · issuer key cusip6:45258J | trim | −$22.5M | −880,000 | $28.2M | $5.7M | 1,110,000 | 230,000 | |
MBX BIOSCIENCES INC COMposition key sid:sec:prov:1910147dd0682cb840152de5838d5484 · issuer key cusip6:55287L | trim | −$7.6M | −230,003 | $12.9M | $5.3M | 408,900 | 178,897 | |
IMMUNIC INC COMposition key sid:sec:prov:4629488a5d372449ffa54969c78cc5e4 · issuer key cusip6:4525EP | new | +$5.0M | +4,500,000 | $0 | $5.0M | — | 4,500,000 | |
LARIMAR THERAPEUTICS INC COMposition key sid:sec:prov:853ca021ff04669801b685877f2dabbb · issuer key cusip6:517125 | new | +$4.8M | +1,066,960 | $0 | $4.8M | — | 1,066,960 | |
ETON PHARMACEUTICALS INC COMposition key sid:sec:prov:a6062b7020b087adc81a7c6d38642d39 · issuer key cusip6:29772L | new | +$4.1M | +166,381 | $0 | $4.1M | — | 166,381 | |
SAB BIOTHERAPEUTICS INC COM NEWposition key sid:sec:prov:03d750f8ea50214fdbd147c22363d0f6 · issuer key cusip6:78397T | new | +$4.0M | +1,050,000 | $0 | $4.0M | — | 1,050,000 | |
PROCEPT BIOROBOTICS CORP COMposition key sid:sec:prov:84385008a6354d52d8f431948b8d3d1e · issuer key cusip6:74276L | new | +$4.0M | +160,000 | $0 | $4.0M | — | 160,000 | |
STRUCTURE THERAPEUTICS INC SPONSORED ADSposition key sid:sec:prov:862b191ccb923fc424f39385b48ce4f8 · issuer key cusip6:86366E | trim | −$2.4M | −10,000 | $6.3M | $3.9M | 90,000 | 80,000 | |
TECTONIC THERAPEUTIC INC COMposition key sid:sec:prov:ab98bdc5d9f0946c8554aa4745533ba5 · issuer key cusip6:878972 | new | +$3.8M | +121,684 | $0 | $3.8M | — | 121,684 | |
PULMONX CORP COMposition key sid:sec:prov:d2d26810594465634746ea83805ad7e9 · issuer key cusip6:745848 | add | −$908K | +750,000 | $4.5M | $3.6M | 2,038,323 | 2,788,323 | |
IOVANCE BIOTHERAPEUTICS INC COMposition key sid:sec:prov:aca3aee6eccb69fff82edb5a5d294e77 · issuer key cusip6:462260 | new | +$3.5M | +1,000,000 | $0 | $3.5M | — | 1,000,000 | |
ARGENX SE SPONSORED ADRposition key pos:18170 · issuer key iss:242 | trim | −$24.1M | −28,226 | $26.7M | $2.6M | 31,726 | 3,500 | |
SATELLOS BIOSCIENCE INC COMposition key sid:sec:prov:c560957b5581c9f7aa7d0a8046845dcb · issuer key cusip6:80401L | new | +$2.3M | +414,359 | $0 | $2.3M | — | 414,359 | |
ARROWHEAD PHARMACEUTICALS IN COMposition key pos:16618 · issuer key iss:249 | new | +$1.8M | +28,479 | $0 | $1.8M | — | 28,479 | |
INSPIREMD INC COMposition key sid:sec:prov:4f3f0dbc6f010cb94ff5053ef428025c · issuer key cusip6:45779A | trim | −$342K | −104,292 | $2.0M | $1.7M | 1,150,000 | 1,045,708 | |
INSMED INC COM PAR $.01position key pos:15087 · issuer key iss:1181 | trim | −$6.8M | −38,250 | $8.4M | $1.7M | 48,500 | 10,250 | |
CYTOMX THERAPEUTICS INC. COMposition key sid:sec:prov:16b2967c1b0bb76b6346bfde109e0bb6 · issuer key cusip6:23284F | new | +$1.4M | +300,000 | $0 | $1.4M | — | 300,000 | |
CG ONCOLOGY INC COMposition key pos:12402 · issuer key iss:558 | trim | −$5.7M | −150,000 | $7.1M | $1.4M | 170,000 | 20,000 | |
NEOGENOMICS INC COM NEWposition key pos:18549 · issuer key iss:1542 | trim | −$3.7M | −252,504 | $5.0M | $1.3M | 427,504 | 175,000 | |
QUOIN PHARMACEUTICALS LTD SPONSORED ADSposition key sid:sec:prov:80b2dc76650ba8570604605af72092bf · issuer key cusip6:74907L | add | +$119K | +47,730 | $361K | $480K | 25,000 | 72,730 | |
COGENT BIOSCIENCES INC COMposition key pos:18333 · issuer key iss:610 | trim | −$3.9M | −110,000 | $4.3M | $385K | 120,000 | 10,000 | |
TYRA BIOSCIENCES INC COMposition key sid:sec:prov:47170149b82e95e4444c881acffa67fc · issuer key cusip6:90240B | trim | −$2.9M | −115,000 | $3.3M | $383K | 125,000 | 10,000 | |
STAAR SURGICAL CO COM PAR $0.01position key sid:sec:prov:ca11044044ffdef73864119b9879be03 · issuer key cusip6:852312 | trim | −$203K | −5,000 | $577K | $374K | 25,000 | 20,000 | |
ANAPTYSBIO INC COMposition key pos:18179 · issuer key iss:200 | trim | −$6.2M | −129,000 | $6.5M | $333K | 135,000 | 6,000 | |
RAPPORT THERAPEUTICS INC COMposition key sid:sec:prov:9fd554b76cc510ac236cd887d1f06195 · issuer key cusip6:75383L | new | +$313K | +10,000 | $0 | $313K | — | 10,000 | |
RIGEL PHARMACEUTICALS INC COMposition key sid:sec:prov:fd7b61c158906c86402255a51c19f819 · issuer key cusip6:766559 | trim | −$12.6M | −290,034 | $12.9M | $270K | 300,034 | 10,000 | |
ZYMEWORKS INC COMposition key sid:sec:prov:cc436d9af4067ff4382c62284d4ff9e5 · issuer key cusip6:98985Y | trim | −$2.4M | −90,000 | $2.6M | $250K | 100,000 | 10,000 | |
ORUKA THERAPEUTICS INC COMposition key pos:14688 · issuer key iss:1638 | trim | −$5.5M | −185,000 | $5.8M | $245K | 190,000 | 5,000 | |
JASPER THERAPEUTICS INC COM NEWposition key sid:sec:prov:9c89115e7db9beb584c246be98849529 · issuer key cusip6:471871 | add | −$124K | +76,312 | $366K | $242K | 200,000 | 276,312 | |
| pos:10981 PUT | exit‡e | −$354M | −2,900,000 | $354M | $0 | 2,900,000 | — | |
| pos:11452 | exit‡e | −$3.6M | −100,000 | $3.6M | $0 | 100,000 | — | |
| pos:12315 | exit‡e | −$25.0M | −175,982 | $25.0M | $0 | 175,982 | — | |
| pos:12600 | exit‡e | −$8.0M | −2,162,162 | $8.0M | $0 | 2,162,162 | — | |
| pos:13227 | exit‡e | −$6.1M | −45,000 | $6.1M | $0 | 45,000 | — | |
| pos:13498 | exit‡e | −$941K | −11,000 | $941K | $0 | 11,000 | — | |
| pos:14578 | exit‡e | −$196K | −10,000 | $196K | $0 | 10,000 | — | |
| pos:14811 | exit‡e | −$1.7M | −69,874 | $1.7M | $0 | 69,874 | — | |
| pos:15238 | exit‡e | −$291K | −500 | $291K | $0 | 500 | — | |
| pos:16974 | exit‡e | −$31.3M | −639,000 | $31.3M | $0 | 639,000 | — | |
| pos:17085 | exit‡e | −$23.2M | −190,000 | $23.2M | $0 | 190,000 | — | |
| pos:17730 | exit‡e | −$2.5M | −70,000 | $2.5M | $0 | 70,000 | — | |
| pos:18040 | exit‡e | −$18.4M | −92,500 | $18.4M | $0 | 92,500 | — | |
| pos:18385 | exit‡e | −$8.6M | −212,710 | $8.6M | $0 | 212,710 | — | |
| sid:sec:prov:0983c227d7f489fadce1abda0a417532 | exit‡e | −$25.9M | −764,000 | $25.9M | $0 | 764,000 | — | |
| sid:sec:prov:38a603ca9db8667eb0886b5fba5cc3fe | exit‡e | −$4.5M | −683,904 | $4.5M | $0 | 683,904 | — |
80 more changes below.
1–100 of 111 changes
Mark-to-market only (no share change) · 9
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
Positionposition matched across quarters by exact reported CUSIP over a registry gap — producer-reconciled identity, never a name match identity_reconciled_by_cusip | Changethe reported share count is unchanged across the pair, so the position reads as held rather than as a buy or a sell; only builds before this release inferred a direction from the reported value instead classified_by_value · "exit" = absent this quarter: disposed, delisted, under confidential treatment, or reported instead by an affiliated manager — the filing does not say which · change not classifiable: value undisclosed on one side of the quarter pair, or neither shares nor value can classify it · "no change" = the share count is identical in both quarters; the value moved only with price, so the row is mark-to-market and never an add or a trim (Add / New / Trim / Exit / No change) · "no prior" = this filer has no comparable holdings list for the previous quarter on record — a first filing under this registration, or a quarter reported inside an affiliated manager's filing — so the position is not called a new stake | Δ valuederived by Public Filings from the published aggregate; NULL means the source did not disclose a usable value — never zero | Δ shares | Prev value | Curr value | Prev shares | Curr shares | Flags |
|---|---|---|---|---|---|---|---|---|
EDAP TMS S A SPONSORED ADRposition key sid:sec:prov:229e14d74796ced76bf47c69ba76757e · issuer key cusip6:268311 | no change | +$3.1M | 0 | $24.0M | $27.2M | 7,309,254 | 7,309,254 | |
PHARVARIS N V COMposition key pos:15462 · issuer key iss:2706 | no change | +$351K | 0 | $19.5M | $19.8M | 702,052 | 702,052 | |
INHIBIKASE THERAPEUTICS INC COM NEWposition key sid:sec:prov:8cb65945c1d745d32abfa3ce25a4d2e9 · issuer key cusip6:45719W | no change | −$4.0M | 0 | $22.3M | $18.3M | 10,875,000 | 10,875,000 | |
JADE BIOSCIENCES INC COM NEWposition key sid:sec:prov:3b4a08cf659449a1ac1d2ee41e501b50 · issuer key cusip6:008064 | no change | −$1.1M | 0 | $12.3M | $11.2M | 796,744 | 796,744 | |
INVIVYD INC COMposition key sid:sec:prov:de0907d604dc0fc94b1a3f8dd009ab9f · issuer key cusip6:00534A | no change | −$9.0M | 0 | $19.0M | $10.0M | 7,708,727 | 7,708,727 | |
C4 THERAPEUTICS INC COM STKposition key sid:sec:prov:d5b8ae591253ff1bf9b2d55cf805085a · issuer key cusip6:12529R | no change | +$2.7M | 0 | $7.3M | $10.0M | 3,803,942 | 3,803,942 | |
AVALO THERAPEUTICS INC COM NEWposition key sid:sec:prov:37b91915f07af95197894a79df85a91e · issuer key cusip6:05338F | no change | −$1.4M | 0 | $8.0M | $6.6M | 441,978 | 441,978 | |
KARYOPHARM THERAPEUTICS INC COM NEWposition key sid:sec:prov:da6009df94d75bf6125e284a1e4e13f1 · issuer key cusip6:48576U | no change | −$788K | 0 | $3.2M | $2.5M | 440,000 | 440,000 | |
LB PHARMACEUTICALS INC COM SHSposition key sid:sec:prov:be515631054470e2500985b7cc1d1245 · issuer key cusip6:50180M | no change | +$24.0K | 0 | $223K | $247K | 10,000 | 10,000 |
Quarter ended 2026-03-31Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
Changes derive from the aggregate's top-25 slices and keyable positions only; unkeyable holdings are counted in the registry, not differenced. methodology §13F ↗
Book shape
2026-03-31 · concentration · vs tracked median · tick = median- Top-25 concentration
- 76.1%below median 80.0%
- Concentration index
- 380 bpsbelow median 446 bps
- Positions with value
- 93 / 93median book 97.5 positions
Concentration uses reported 13F long value, not total assets. The index is withheld when any position lacks a value. Medians are over the 8,748 tracked filers with a 2026-03-31 book; the index median over the 8,662 with a complete book.
null-value positions: 0holdings whose <value> did not parse — retained and counted, never zero-filled · top-N share ·§: 76.1% · HHI (bps) ·§: 380integer Herfindahl–Hirschman index in basis points over disclosed position values · QoQ moves: 120
Filing history
AVAILABLE QUARTERS| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
PLANNED sector rotation · Congress overlap · signals for this filer
Complete source filings on SEC EDGAR
The complete filing on EDGAR.
The position list above is served from the published Public Filings build — every position this filer reported for the selected quarter, as it reported it. This block is provenance, not a substitute: the filing itself is the record, and it is one click away. Serving this list is M2-CONTRACT §3, amended 2026-08-02; §3.1 keeps live EDGAR for filings newer than this build.
Open Soleus Capital Management, L.P.'s 13F filings on SEC EDGAR ↗Notes on this data
Share changes
Compare consecutive quarters
Position changes retain the producer’s classification and comparability flags. Share counts and reported values describe different changes.
Coverage
A snapshot, not current holdings
Use the quarter selector to inspect available periods. Unknown values stay unknown and each table states its coverage.
ViewPrior quarter not yet availableThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
Reported positions — 2026-03-31
1–93 of 93 positions · $2.5B disclosed value over 93 rows · 0 undisclosed-value rowsEvery row below carries ticker not yet mapped — stated once here rather than repeated on every row.
| KindClassification is not joined into this reported-position view. Use the changed-positions view to compare the two published quarters. | TickerThis list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | Issuera position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | WeightShare of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | Valuevalue undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Position changeShare change is available in the separate comparison view; it is not joined into this position list. | Wt | CongressThe congressional transaction join is unavailable in this build. |
|---|---|---|---|---|---|---|---|---|
| — | KRYSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KRYSTAL BIOTECH INC KRYSTAL BIOTECH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $298M | 1,153,087 | — | 12.1% | — | |
| — | CELCverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $147M | 1,284,378 | — | 5.9% | — | |
| — | TGTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TG THERAPEUTICS INC TG THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $134M | 4,029,319 | — | 5.4% | — | |
| — | PODDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSULET CORP INSULET CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $118M | 562,500 | — | 4.8% | — | |
| — | — | NOVOCURE LTD NOVOCURE LTD · ORD SHS CUSIP G6674U108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $114M | 10,492,391 | — | 4.6% | — | |
| — | UTHRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | UNITED THERAPEUTICS CORP DEL UNITED THERAPEUTICS CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $111M | 187,187 | — | 4.5% | — | |
| — | PRAXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PRAXIS PRECISION MEDICINES I PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $106M | 330,517 | — | 4.3% | — | |
| — | VCELverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERICEL CORP VERICEL CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $82.0M | 2,549,079 | — | 3.3% | — | |
| — | ALKSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALKERMES PLC ALKERMES PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $69.7M | 1,970,864 | — | 2.8% | — | |
| — | ANIPverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ANI PHARMACEUTICALS INC ANI PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $63.1M | 820,243 | — | 2.6% | — | |
| — | GMEDverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GLOBUS MED INC GLOBUS MED INC · CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $62.9M | 729,467 | — | 2.5% | — | |
| — | — | GERON CORP GERON CORP · COM CUSIP 374163103 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $61.8M | 41,508,659 | — | 2.5% | — | |
| — | TWSTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TWIST BIOSCIENCE CORP TWIST BIOSCIENCE CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $58.3M | 1,226,629 | — | 2.4% | — | |
| — | EWTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDGEWISE THERAPEUTICS INC EDGEWISE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $45.7M | 1,449,915 | — | 1.8% | — | |
| — | — | BETA BIONICS INC BETA BIONICS INC · COM CUSIP 08659B102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $43.6M | 4,354,501 | — | 1.8% | — | |
| — | ALNYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALNYLAM PHARMACEUTICALS INC ALNYLAM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $43.6M | 131,650 | — | 1.8% | — | |
| — | — | SYNDAX PHARMACEUTICALS INC SYNDAX PHARMACEUTICALS INC · COM CUSIP 87164F105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $40.3M | 1,726,908 | — | 1.6% | — | |
| — | INDVverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INDIVIOR PHARMACEUTICALS INC INDIVIOR PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $38.8M | 1,274,000 | — | 1.6% | — | |
| — | — | NEUROPACE INC NEUROPACE INC · COM CUSIP 641288105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $38.6M | 2,932,207 | — | 1.6% | — | |
| — | LIVNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LIVANOVA PLC LIVANOVA PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $37.0M | 582,500 | — | 1.5% | — | |
| — | MIRMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MIRUM PHARMACEUTICALS INC MIRUM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $37.0M | 400,306 | — | 1.5% | — | |
| — | BMRNverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOMARIN PHARMACEUTICAL INC BIOMARIN PHARMACEUTICAL INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $36.8M | 650,572 | — | 1.5% | — | |
| — | PGNYverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PROGYNY INC PROGYNY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $35.1M | 2,067,000 | — | 1.4% | — | |
| — | INSPverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSPIRE MED SYS INC INSPIRE MED SYS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $29.7M | 576,299 | — | 1.2% | — | |
| — | — | EDAP TMS S A EDAP TMS S A · SPONSORED ADR CUSIP 268311107 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $27.2M | 7,309,254 | — | 1.1% | — | |
| — | KNSAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | KINIKSA PHARMACEUTICALS INTL KINIKSA PHARMACEUTICALS INTL · ORD SHS CL A CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $25.1M | 521,353 | — | 1.0% | — | |
| — | MRKverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MERCK & CO INC MERCK & CO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $24.4M | 203,000 | — | 1.0% | — | |
| — | — | ORGANOGENESIS HLDGS INC ORGANOGENESIS HLDGS INC · COM CUSIP 68621F102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $23.9M | 10,085,951 | — | 1.0% | — | |
| — | NTRAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NATERA INC NATERA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $23.8M | 119,000 | — | 1.0% | — | |
| — | — | AXOGEN INC AXOGEN INC · COM CUSIP 05463X106 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $22.5M | 679,170 | — | 0.9% | — | |
| — | PCVXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VAXCYTE INC VAXCYTE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $22.4M | 385,472 | — | 0.9% | — | |
| — | ICLRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ICON PLC ICON PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $21.2M | 192,000 | — | 0.9% | — | |
| — | PHVSverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PHARVARIS N V PHARVARIS N V · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $19.8M | 702,052 | — | 0.8% | — | |
| — | — | CERUS CORP CERUS CORP · COM CUSIP 157085101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $19.6M | 10,753,700 | — | 0.8% | — | |
| — | TRVIverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TREVI THERAPEUTICS INC TREVI THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $19.3M | 1,620,000 | — | 0.8% | — | |
| — | — | INHIBIKASE THERAPEUTICS INC INHIBIKASE THERAPEUTICS INC · COM NEW CUSIP 45719W205 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $18.3M | 10,875,000 | — | 0.7% | — | |
| — | — | CONTEXT THERAPEUTICS INC CONTEXT THERAPEUTICS INC · COM CUSIP 21077P108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $18.2M | 6,963,141 | — | 0.7% | — | |
| — | VIRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VIR BIOTECHNOLOGY INC VIR BIOTECHNOLOGY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $17.9M | 2,002,000 | — | 0.7% | — | |
| — | XENEverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | XENON PHARMACEUTICALS INC XENON PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $17.0M | 292,000 | — | 0.7% | — | |
| — | TVTXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TRAVERE THERAPEUTICS INC TRAVERE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $16.2M | 546,000 | — | 0.7% | — | |
| — | — | TANDEM DIABETES CARE INC TANDEM DIABETES CARE INC · COM NEW CUSIP 875372203 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $15.0M | 783,000 | — | 0.6% | — | |
| — | — | NURIX THERAPEUTICS INC NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $14.5M | 938,163 | — | 0.6% | — | |
| — | — | UROGEN PHARMA LTD UROGEN PHARMA LTD · COM CUSIP M96088105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $13.1M | 727,000 | — | 0.5% | — | |
| — | SIONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SIONNA THERAPEUTICS INC SIONNA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $11.8M | 293,500 | — | 0.5% | — | |
| — | CORTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CORCEPT THERAPEUTICS INC CORCEPT THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $11.5M | 285,531 | — | 0.5% | — | |
| — | — | JADE BIOSCIENCES INC JADE BIOSCIENCES INC · COM NEW CUSIP 008064206 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $11.2M | 796,744 | — | 0.5% | — | |
| — | VCYTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERACYTE INC VERACYTE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $10.3M | 319,912 | — | 0.4% | — | |
| — | — | INVIVYD INC INVIVYD INC · COM CUSIP 00534A102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $10.0M | 7,708,727 | — | 0.4% | — | |
| — | — | C4 THERAPEUTICS INC C4 THERAPEUTICS INC · COM STK CUSIP 12529R107 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $10.0M | 3,803,942 | — | 0.4% | — | |
| — | — | ORTHOPEDIATRICS CORP ORTHOPEDIATRICS CORP · COM CUSIP 68752L100 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $9.8M | 615,447 | — | 0.4% | — | |
| — | — | ARCUS BIOSCIENCES INC ARCUS BIOSCIENCES INC · COM CUSIP 03969F109 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $9.8M | 451,983 | — | 0.4% | — | |
| — | TNGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TANGO THERAPEUTICS INC TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $9.4M | 450,000 | — | 0.4% | — | |
| — | — | EVOLUS INC EVOLUS INC · COM CUSIP 30052C107 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $9.2M | 2,245,360 | — | 0.4% | — | |
| — | — | SOPHIA GENETICS SA SOPHIA GENETICS SA · ORDINARY SHARES CUSIP H82027105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $9.2M | 1,850,000 | — | 0.4% | — | |
| — | — | ENLIVEN THERAPEUTICS INC ENLIVEN THERAPEUTICS INC · COM CUSIP 29337E102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $9.1M | 230,869 | — | 0.4% | — | |
| — | INBXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INHIBRX BIOSCIENCES INC INHIBRX BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $8.8M | 131,000 | — | 0.4% | — | |
| — | DXCMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DEXCOM INC DEXCOM INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $8.8M | 140,000 | — | 0.4% | — | |
| — | — | SEPTERNA INC SEPTERNA INC · COM CUSIP 81734D104 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $6.6M | 275,000 | — | 0.3% | — | |
| — | — | AVALO THERAPEUTICS INC AVALO THERAPEUTICS INC · COM NEW CUSIP 05338F306 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $6.6M | 441,978 | — | 0.3% | — | |
| — | — | BIODESIX INC BIODESIX INC · COM CUSIP 09075X207 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $6.0M | 416,599 | — | 0.2% | — | |
| — | — | RELMADA THERAPEUTICS INC RELMADA THERAPEUTICS INC · COM CUSIP 75955J402 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $5.9M | 842,106 | — | 0.2% | — | |
| — | CGEMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CULLINAN THERAPEUTICS INC CULLINAN THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $5.8M | 410,200 | — | 0.2% | — | |
| — | — | IMMUNOVANT INC IMMUNOVANT INC · COM CUSIP 45258J102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $5.7M | 230,000 | — | 0.2% | — | |
| — | — | MBX BIOSCIENCES INC MBX BIOSCIENCES INC · COM CUSIP 55287L101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $5.3M | 178,897 | — | 0.2% | — | |
| — | — | IMMUNIC INC IMMUNIC INC · COM CUSIP 4525EP101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $5.0M | 4,500,000 | — | 0.2% | — | |
| — | — | LARIMAR THERAPEUTICS INC LARIMAR THERAPEUTICS INC · COM CUSIP 517125100 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $4.8M | 1,066,960 | — | 0.2% | — | |
| — | — | ETON PHARMACEUTICALS INC ETON PHARMACEUTICALS INC · COM CUSIP 29772L108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $4.1M | 166,381 | — | 0.2% | — | |
| — | — | SAB BIOTHERAPEUTICS INC SAB BIOTHERAPEUTICS INC · COM NEW CUSIP 78397T202 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $4.0M | 1,050,000 | — | 0.2% | — | |
| — | — | PROCEPT BIOROBOTICS CORP PROCEPT BIOROBOTICS CORP · COM CUSIP 74276L105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $4.0M | 160,000 | — | 0.2% | — | |
| — | — | STRUCTURE THERAPEUTICS INC STRUCTURE THERAPEUTICS INC · SPONSORED ADS CUSIP 86366E106 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $3.9M | 80,000 | — | 0.2% | — | |
| — | — | TECTONIC THERAPEUTIC INC TECTONIC THERAPEUTIC INC · COM CUSIP 878972108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $3.8M | 121,684 | — | 0.2% | — | |
| — | — | PULMONX CORP PULMONX CORP · COM CUSIP 745848101 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $3.6M | 2,788,323 | — | 0.1% | — | |
| — | — | IOVANCE BIOTHERAPEUTICS INC IOVANCE BIOTHERAPEUTICS INC · COM CUSIP 462260100 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $3.5M | 1,000,000 | — | 0.1% | — | |
| — | ARGXverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARGENX SE ARGENX SE · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $2.6M | 3,500 | — | 0.1% | — | |
| — | — | KARYOPHARM THERAPEUTICS INC KARYOPHARM THERAPEUTICS INC · COM NEW CUSIP 48576U205 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $2.5M | 440,000 | — | 0.1% | — | |
| — | — | SATELLOS BIOSCIENCE INC SATELLOS BIOSCIENCE INC · COM CUSIP 80401L803 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $2.3M | 414,359 | — | 0.1% | — | |
| — | ARWRverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARROWHEAD PHARMACEUTICALS IN ARROWHEAD PHARMACEUTICALS IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $1.8M | 28,479 | — | 0.1% | — | |
| — | — | INSPIREMD INC INSPIREMD INC · COM CUSIP 45779A846 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $1.7M | 1,045,708 | — | 0.1% | — | |
| — | INSMverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSMED INC INSMED INC · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $1.7M | 10,250 | — | 0.1% | — | |
| — | — | CYTOMX THERAPEUTICS INC. CYTOMX THERAPEUTICS INC. · COM CUSIP 23284F105 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $1.4M | 300,000 | — | 0.1% | — | |
| — | CGONverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CG ONCOLOGY INC CG ONCOLOGY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $1.4M | 20,000 | — | 0.1% | — | |
| — | NEOverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEOGENOMICS INC NEOGENOMICS INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $1.3M | 175,000 | — | 0.1% | — | |
| — | — | QUOIN PHARMACEUTICALS LTD QUOIN PHARMACEUTICALS LTD · SPONSORED ADS CUSIP 74907L409 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $480K | 72,730 | — | 0.0% | — | |
| — | COGTverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COGENT BIOSCIENCES INC COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $385K | 10,000 | — | 0.0% | — | |
| — | — | TYRA BIOSCIENCES INC TYRA BIOSCIENCES INC · COM CUSIP 90240B106 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $383K | 10,000 | — | 0.0% | — | |
| — | — | STAAR SURGICAL CO STAAR SURGICAL CO · COM PAR $0.01 CUSIP 852312305 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $374K | 20,000 | — | 0.0% | — | |
| — | ANABverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ANAPTYSBIO INC ANAPTYSBIO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $333K | 6,000 | — | 0.0% | — | |
| — | — | RAPPORT THERAPEUTICS INC RAPPORT THERAPEUTICS INC · COM CUSIP 75383L102 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $313K | 10,000 | — | 0.0% | — | |
| — | — | RIGEL PHARMACEUTICALS INC RIGEL PHARMACEUTICALS INC · COM CUSIP 766559702 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $270K | 10,000 | — | 0.0% | — | |
| — | — | ZYMEWORKS INC ZYMEWORKS INC · COM CUSIP 98985Y108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $250K | 10,000 | — | 0.0% | — | |
| — | — | LB PHARMACEUTICALS INC LB PHARMACEUTICALS INC · COM SHS CUSIP 50180M108 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $247K | 10,000 | — | 0.0% | — | |
| — | ORKAverified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ORUKA THERAPEUTICS INC ORUKA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $245K | 5,000 | — | 0.0% | — | |
| — | — | JASPER THERAPEUTICS INC JASPER THERAPEUTICS INC · COM NEW CUSIP 471871202 quarter ended 2026-03-31 filed filed 2026-05-14 +44d | $242K | 276,312 | — | 0.0% | — |
1–93 of 93 positions · page 1 of 1
every row this filer reported for the quarter, as it reported it — cross-filer de-duplication is applied to issuer totals elsewhere and never deletes a row here
A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings. A position may have been changed or closed before you ever see it, and is older still by however long ago that quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars with unit_basis carried on every record.
Affiliated managers may report the same position (otherManager), so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice (ARCHITECTURE.md §5.2 / M2-CONTRACT §5).